George Georgiou is a Professor at The University of Texas at Austin. He received his B.Sc. from the University of Manchester, U.K. and Ph.D. from Cornell. His research is focused on the discovery and preclinical development of enzyme and antibody therapeutics and the molecular level understanding of the serological antibody repertoire in human health and disease. Professor Georgiou was elected to the National Academy of Engineering (2005), National Academy of Medicine (2011) and the American Academy of Arts and Sciences (2016). He is also a Fellow of the American Institute for Biological and Medical Engineers (AIMBE), the American Academy of Microbiology and the American Association for the Advancement of Science (AAAS). He is the author of >240 research publications and co-inventor of 91 issued or pending US patents, more than 65% of which (comprising 24 distinct technology suites) have been licensed to 27 pharma & biotech companies. He founded GGMJD in 1999 (acquired by Maxygen in 2000), Aeglea Biotherapeutics in 2013 (NASDAQ: AGLE) and Kyn Therapeutics Inc. He currently serves as a Director and for both Aeglea and Kyn. He has been named as one the top “100 Chemical Engineers of the Modern Era” by the American Institute of Chemical Engineers and in 2013 Georgiou was selected as one of the top 20 Translational Researchers by Nature Biotechnology.
The University of Texas at Austin